Evidence map›Paper›PMID 25079173›Full record

Trial reportLeukemia2015

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.

D J DeAngelo, K E Stevenson, S E Dahlberg, L B Silverman, S Couban, J G Supko, P C Amrein, K K Ballen, M D Seftel, A R Turner and 12 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05501899 (Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia), which is not on this map. Cited by 163 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05501899 early_phase1recruitingnot on this mapstarted 2023, after this paper: background citation

Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia

TypeinterventionalSponsorChildren's Hospital of Orange CountyRan2023 to 2024Enrolled20ConditionsAcute Lymphoblastic Leukemia, HepatotoxicityArmsLevocarnitine
3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

D J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
K E StevensonDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
S E DahlbergDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
L B SilvermanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute/Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA.
S Couban1] National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada [2] Dalhousie University, Halifax, Nova Scotia, Canada.
J G SupkoMassachusetts General Hospital, Boston, MA, USA.
P C AmreinMassachusetts General Hospital, Boston, MA, USA.
K K BallenMassachusetts General Hospital, Boston, MA, USA.
M D SeftelCancer Care Manitoba, Winnipeg, Manitoba, Canada.
A R TurnerCross Cancer Institute, Edmonton, Alberta, Canada.
B LeberHamilton Health Sciences Center, Hamilton, Ontario, Canada.
K Howson-JanLondon Health Services, London, Ontario, Canada.
K KellyColumbia University Medical Center, New York, NY, USA.
S CohenHospital Maisonneuve-Rosemont, Montreal, Quebec, Canada.
J H MatthewsQueen's University, Kingston, Ontario, Canada.
L SavoieTom Baker Cancer Center, Calgary, Alberta, Canada.
M WadleighDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
L A SirulnikDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
I GalinskyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
D S NeubergDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
S E SallanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute/Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA.
R M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Funding

Zebrafish Screens for Genetic Modifiers and Human Application in T-ALLP01CA068484 · NCI · DANA-FARBER CANCER INSTITUTE · PI ARMSTRONG, SCOTT A · 1995 to 2010
$31.9M
NCI NIH HHS P01 CA068484
6 · The paper itself

Abstract

On the basis of the data suggesting that adolescents and young adult patients with acute lymphoblastic leukemia (ALL) have improved outcomes when treated on pediatric protocols, we assessed the feasibility of treating adult patients aged 18-50 years with ALL with the DFCI Pediatric ALL Consortium regimen utilizing a 30-week course of pharmacokinetically dose-adjusted E. coli L-asparaginase during consolidation. Between 2002 and 2008, 92 eligible patients aged 18-50 years were enrolled at 13 participating centers. Seventy-eight patients (85%) achieved a complete remission (CR) after 1 month of intensive induction therapy. With a median follow-up of 4.5 years, the 4-year disease-free survival (DFS) for the patients achieving a CR was 69% (95% confidence interval (CI) 56-78%) and the 4-year overall survival (OS) for all eligible patients was 67% (95% CI 56-76%). The 4-year DFS for the 64 patients who achieved a CR and were Philadelphia chromosome negative (Ph-) was 71% (95% CI 58-81%), and for all 74 Ph- patients the 4-year OS was 70% (95% CI 58-79%). We conclude that a pediatric-like treatment strategy for young adults with de novo ALL is feasible, associated with tolerable toxicity, and results in improved outcomes compared with historical regimens in young adult patients with ALL.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAdolescentAdultAsparaginaseCytarabineDoxorubicinDrug Administration ScheduleFemaleHumansKaryotypingMaleMethotrexateMiddle AgedPrecision MedicinePrecursor Cell Lymphoblastic Leukemia-LymphomaPrednisoneAsparaginaseCytarabineDoxorubicinMethotrexatePrednisoneVincristine

Identifiers

PMID25079173
PMCPMC4360211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.